Summary
Cardinal Health Inc. (CAH) reported its Q1 Fiscal Year 2023 results, with total revenue increasing by 13% to $49.6 billion, driven by strong performance in pharmaceutical distribution and specialty pharmaceutical customers. However, GAAP operating earnings saw a significant decline of 67% to $137 million, primarily impacted by a $154 million non-cash goodwill impairment charge in the Medical Segment and a general profit decrease in that segment due to inflationary pressures and lower Personal Protective Equipment (PPE) pricing and volumes. Non-GAAP operating earnings decreased by 20% to $423 million, also largely attributed to the challenges in the Medical segment. Despite these headwinds, the Pharmaceutical segment showed a 6% increase in profit. The company also made a $372 million annual payment related to the opioid litigation settlement and repurchased $1.0 billion of its common shares. Management believes the company has adequate capital resources to meet its obligations, but acknowledges potential impacts from inflationary pressures, supply chain disruptions, and ongoing litigation. Key financial takeaways include a substantial goodwill impairment, reduced operating earnings despite revenue growth, and continued investment in share buybacks. Investors should monitor the Medical segment's performance, the ongoing impact of inflation, and the resolution of significant legal matters, particularly the opioid litigation, which continues to represent a substantial financial commitment.
Financial Highlights
47 data points| Revenue | $49.59B |
| Cost of Revenue | $48.00B |
| Gross Profit | $1.60B |
| SG&A Expenses | $1.20B |
| Operating Income | $123.00M |
| Interest Expense | $24.00M |
| Net Income | $98.00M |
| EPS (Basic) | $0.36 |
| EPS (Diluted) | $0.36 |
| Shares Outstanding (Basic) | 271.00M |
| Shares Outstanding (Diluted) | 273.00M |
Key Highlights
- 1Revenue increased by 13% to $49.6 billion, driven by the Pharmaceutical segment's growth in distribution and specialty pharmaceutical sales.
- 2GAAP operating earnings decreased by 67% to $137 million, largely due to a $154 million goodwill impairment charge in the Medical Segment.
- 3Non-GAAP operating earnings decreased by 20% to $423 million, reflecting challenges in the Medical segment, including inflationary impacts and lower PPE pricing/volumes.
- 4The Medical segment's profit declined significantly, impacted by inflation, decreased PPE demand and pricing, and inventory charges.
- 5The Pharmaceutical segment demonstrated resilience with a 6% increase in profit, supported by generics and branded pharmaceutical sales.
- 6The company made its second annual opioid litigation settlement payment of $372 million and repurchased $1.0 billion of its common stock.
- 7Cash and equivalents decreased to $3.5 billion from $4.7 billion, reflecting operating cash flow of $23 million and significant share repurchases.